Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 4Vomiting 3Nausea 2Anorexia 2Weight Loss 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Opioid-Related Disorders 1Muscular Atrophy 1Multiple Myeloma 1Lung Neoplasms 1Hematologic Neoplasms 1Gynecologic Cancer 1Gliosarcoma 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Child Nutrition Disorders 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Neoplasms 1

Interventions

Fulvestrant 125Trastuzumab 114Paclitaxel 113Letrozole 108pembrolizumab 79pertuzumab 75palbociclib 75Capecitabine 72Anastrozole 72Cyclophosphamide 70Carboplatin 67abemaciclib 64exemestane 63Tamoxifen 63ribociclib 60trastuzumab deruxtecan 57Surveys and Questionnaires 51Specimen Handling 50Radiotherapy 49Docetaxel 49Magnetic Resonance Spectroscopy 48Blood Specimen Collection 40olaparib 39Standard of Care 36Biopsy 33sacituzumab govitecan 31130-nm albumin-bound paclitaxel 31Doxorubicin 30Exercise 29eribulin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Olanzapine × 1 year × Clear all
NCT03367572 2025-09-25

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

University of Rochester

Phase 3 Completed
1,363 enrolled 20 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡